fondaparinux / Generic mfg. - LARVOL DELTA

ANTICOAGULANT - ASSOCIATED ACUTE KIDNEY INJURY: A PHARMACOVIGILANCE ANALYSIS BASED ON FDA ADVERSE EVENT REPORTING SYSTEM (ISN-WCN 2026) - "A).Warfarin had stable low reports, while newer oral anticoagulants (NOACs) showed dramatic trends: Apixaban peaked over 20,000 around 2021, Rivaroxaban near 20,000 in 2015, Dabigatran over 11,000 in 2012. Drugs like Argatroban, Bivalirudin, and Dalteparin had consistently low reports (Fig...Results show heterogeneity in renal ADRs; Fondaparinux and Apixaban signal specific toxicities. Findings can guide pharmacovigilance and clinical decisions for renal risk patients."

Adverse events • Acute Kidney Injury • Nephrology • Renal Disease • ROR1

Anticoagulation Practices in Antiphospholipid Syndrome: A Retrospective Chart Review (THSNA 2026) - "Notably, the TRAPS trial, which compared rivaroxaban to warfarin in triple-positive APS patients, was terminated early due to excess thrombotic events in the rivaroxaban group. Similarly, the ASTRO-APS trial, comparing apixaban to warfarin, was halted early because of a high rate of thrombotic stroke in the apixaban arm...Comparisons between groups (DOAC vs. warfarin/LMWH/fondaparinux) will be performed using the chi-square test or Fisher's exact test, as appropriate, for categorical variables. Differences in patient characteristics between these groups will be assessed using chi-square tests for categorical variables and t-tests or Mann-Whitney U tests for continuous variables, as appropriate. Results Research in Progress Conclusion Research in Progress No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written..."

Retrospective data • Review • Cardiovascular • Genetic Disorders • Hematological Disorders • Ischemic stroke • Venous Thromboembolism

Optimizing Anticoagulant Strategies in Pregnancy-Associated HIT and Acute Stroke in a Real-World Community Setting (THSNA 2026) - "Case Presentation: A 30-year-old gravid 1 para 0 woman with a history of unprovoked lower-extremity deep vein thrombosis (DVT), maintained on rivaroxaban for secondary prophylaxis, was transitioned to LMWH (enoxaparin) at 7 weeks' gestation...Enoxaparin was discontinued, and argatroban was initiated post-EVT, followed by transition to subcutaneous danaparoid and ultimately fondaparinux for ongoing anticoagulation through pregnancy...This case demonstrates that, when supported by coordinated multidisciplinary expertise, community hospitals can effectively deliver highly specialized, patient-centered thrombosis care. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author."

Clinical • Real-world • Real-world evidence • Cardiovascular • Hematological Disorders • Ischemic stroke • Thrombocytopenia • Thrombosis

Comprehensive Evaluation of HIT Outcomes: Ongoing Thrombotic Complications Despite Standard Therapy (THSNA 2026) - "Among these patients, 27 (73%) were treated with Argatroban, 6 (16%) with bivalirudin, 1 (2.7%) with fondaparinux, and 2 (5.4%) with apixaban. HIT remains a highly morbid and life-threatening condition, with prolonged hospitalizations, high rates of both thrombotic and bleeding complications, and substantial ICU utilization. Thrombotic events occurred even among patients who were promptly treated, highlighting the persistent risk despite appropriate management. Further studies are needed to better identify which patients are at highest risk for severe complications."

Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis

MERCURION-IPF: Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P3 | N=196 | Recruiting | Sponsor: Argyrios Tzouvelekis | Not yet recruiting ➔ Recruiting

Enrollment open • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Adrenal hemorrhage requiring apixaban reversal in the setting of active deep vein thrombosis and heparin-induced thrombocytopenia: A case report. (PubMed, Am J Health Syst Pharm) - "This case illustrates the intersection of BAH, active thrombosis, and HIT, where guideline-directed reversal strategies are limited. It underscores the challenges of selecting and timing anticoagulation reversal in patients with recent thrombotic events and contraindications to standard agents, highlighting the importance of individualized, interdisciplinary decision-making in managing complex anticoagulation scenarios."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Mood Disorders • Orthopedics • Septic Shock • Thrombocytopenia • Thrombosis • Venous Thromboembolism

Antithrombotic Therapy and Their Association with Periprosthetic Joint Infection Risk after Total Knee Arthroplasty: A 12-Year Review (AAOS 2026) - "Apixaban usage increased gradually, reaching 10% by 2025...In contrast, enoxaparin (2.10% vs. 1.11%, p = 0.0001) and fondaparinux (3.62% vs. 1.22%, p = 0.028) were associated with higher infection risk... Over the past decade, aspirin has emerged as the most commonly used postoperative ATT agent following TKA and is associated with reduced risk of PJI. Conversely, declining use of enoxaparin and other non-aspirin regimens was observed and was also found to be associated with higher infection risk, albeit with small effect sizes."

Review • Infectious Disease • Orthopedics • Pain

VALIDATION OF THE HEPARIN-INDUCED THROMBOCYTOPENIA DIAGNOSIS CODE USING A LARGE-SCALE ELECTRONIC HEALTH RECORD DATABASE (ISPOR 2026) - "This study uses a diagnostically complex condition to highlight the importance of using laboratory-confirmed diagnosis codes in pharmacoepidemiology studies, particularly for conditions with low prevalence, as the predictive value of the diagnosis code itself did not reliably predict HIT."

Hematological Disorders • Thrombocytopenia

Complexities of Anticoagulants and Reversal Agents on VADs (ISHLT 2026) - "Direct thrombin inhibitors, Heparin, Warfarin and Fondaparinux will be discussed, as well as Andexanant and prothrombin concentrate complex. A case presentation will highlight antithrombotic choice and reversal strategy: pausing, or reversal agent and associated risks. A 5-minute audience Q&A will follow."

Acute venous disorders: deep vein thrombosis and superficial vein thrombosis of the lower extremity : Diagnosis and treatment in dermatology practice (PubMed, Dermatologie (Heidelb)) - "Structured risk stratification, focused diagnostic work-up, and guideline-concordant therapy are essential to prevent thromboembolic complications."

Journal • Review • Cardiovascular • Dermatology • Hematological Disorders • Pulmonary Embolism • Respiratory Diseases • Thrombosis • Venous Thromboembolism

Adverse event profile of fondaparinux sodium: a disproportionality analysis based on FAERS, JADER, and VigiAccess databases. (PubMed, Front Med (Lausanne)) - "While our findings align with established adverse reaction profiles, they also highlight potential novel signals that warrant further investigation. These insights provide valuable reference points for clinical monitoring, particularly in special populations, though further epidemiological studies are needed to verify causality."

Adverse events • Journal • Cardiovascular • Hematological Disorders • Myocardial Infarction • Orthopedics • Pediatrics • Venous Thromboembolism

IVC syndrome in a patient with Factor V Leiden mutation. (PubMed, BMJ Case Rep) - "She was subtherapeutic on heparin and was started on argatroban. On discharge, she was transitioned to fondaparinux."

Journal • Cardiovascular • Critical care • Hematological Disorders • Pain • Thrombosis

Autoimmune heparin-induced thrombocytopenia following cardiac surgery. (PubMed, BMJ Case Rep) - "Anticoagulation was changed to argatroban plus high-dose intravenous immunoglobulin. Persisting hypercoagulability prompted a switch to fondaparinux, with gradual platelet count recovery (155×109/L, POD62); neurological abnormalities resolved. Laboratory evaluation confirmed HIT antibodies with heparin-independent platelet-activating properties, indicating autoimmune HIT (aHIT). Besides profound thrombocytopenia (platelet count nadir, 13×10⁹/L), novel aspects of this case of aHIT include early postoperative onset (before POD5) resulting from preoperative heparin exposure and a unique laboratory aHIT antibody profile with partial resistance to Fc receptor blockade."

Journal • Cardiovascular • Hematological Disorders • Immunology • Thrombocytopenia

How French vascular physicians treat cancer associated superficial vein thrombosis? (PubMed, Vasc Dis (Paris)) - "This survey reveals substantial variability in the treatment of cancer-associated SVT. The absence of dedicated trials and specific recommendations highlights the urgent need for prospective studies to guide management in this complex clinical setting."

Journal • Cardiovascular • Hematological Disorders • Oncology • Thrombosis

Disproportionality analysis of fondaparinux associated adverse events based on the FDA adverse event reporting system. (PubMed, PLoS One) - "Heightened pharmacovigilance particularly in older adults may be warranted. This study enhances understanding of fondaparinux's safety, providing insights for reducing risks and ensuring safer clinical application."

Adverse events • Journal • Acute Coronary Syndrome • Cardiovascular • Eosinophilia • Hematological Disorders • Thrombocytopenia • Venous Thromboembolism

Case Report: A multidisciplinary, protocol-driven pathway from recurrent pregnancy loss to live birth in an anti-Ro/SSA-positive primary Sjögren's syndrome pregnancy with literature review. (PubMed, Front Immunol) - "A multidisciplinary protocol was implemented, including hydroxychloroquine 400 mg/day, methylprednisolone (initially 6 mg/day, briefly increased to 32 mg/day at 14-16 weeks, then tapered to 8 mg/day), low-dose aspirin 50 mg/day, and fondaparinux 2.5 mg/day from ovulation throughout pregnancy, along with scheduled intravenous immunoglobulin (IVIG; 20 g at 4, 6 + 6, and 8 + 2 weeks; followed by 20 g/day × 3 at 14, 18, and 22weeks)...Postpartum, the mother continued methylprednisolone 6 mg/day, hydroxychloroquine 400 mg daily, and enoxaparin 4,000 IU once daily for 4 weeks maintain disease suppression and thromboprophylaxis. In an anti-Ro/SSA-positive pregnancy at extreme risk, a prevention-first, protocol-driven approach-centered on hydroxychloroquine, judicious immunomodulation, and structured AV-interval surveillance-successfully averted CAVB and resulted in a pacemaker-free live birth. Minor cardiac lesions warrant ongoing follow-up;..."

Journal • Review • Cardiovascular • CNS Disorders • Hematological Disorders • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Sjogren's Syndrome

Current Trends in Venous Thromboprophylaxis for Inpatient Care. (PubMed, J Pers Med) - "The aim of the present review is to provide a structured synthesis of the current evidence on thromboprophylaxis strategies in hospitalized patients, critically appraise the performance and applicability of existing VTE and bleeding risk models and highlight how these tools can guide a tailored illness-specific approach to prophylactic decision-making. Where relevant, the review also outlines practical, risk-adapted algorithms to optimize thromboprophylaxis across diverse clinical settings."

Journal • Review • Cardiovascular • Hematological Disorders • Venous Thromboembolism

Safety Profile and Bleeding Complications of Fondaparinux Versus Enoxaparin in Non-ST Elevation Acute Coronary Syndrome. (PubMed, Cureus) - "Conclusions Fondaparinux demonstrates superior safety and effectiveness over enoxaparin in reducing bleeding complications and ischemic events among NSTE-ACS patients. These findings support its preferential use in resource-constrained clinical settings."

Journal • Acute Coronary Syndrome • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Hypertension • Metabolic Disorders • Myocardial Infarction

Fondaparinux-associated thrombocytopenia as a cause of bilateral pulmonary embolism. (PubMed, Med Clin (Barc)) - No abstract available

Journal • Cardiovascular • Hematological Disorders • Pulmonary Embolism • Respiratory Diseases • Thrombocytopenia

Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial. (PubMed, JAMA) - P=N/A | "Physicians and patients selected any DOAC or any LMWH (or fondaparinux) and physicians selected drug doses...These findings support use of a DOAC to prevent recurrent VTE in patients with cancer. ClinicalTrials.gov Identifier: NCT02744092."

Clinical • Journal • Cardiovascular • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Oncology • Solid Tumor • Venous Thromboembolism

EFFICACY AND SAFETY OF DOACS FOR THE TREATMENT OF SUPERFICIAL VEIN THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. (PubMed, Thromb Haemost) - "DOACs demonstrate efficacy comparable to fondaparinux and an excellent safety profile in SVT, supporting their use as a practical oral alternative. Long-term data indicate persistent thrombotic risk, suggesting potential benefit of extended low-dose prophylaxis in selected high-risk patients."

Journal • Retrospective data • Cardiovascular • Hematological Disorders • Respiratory Diseases • Thrombosis • Venous Thromboembolism

Rational design of heparin antagonist: Guanidine-based mimetics unveil key carbohydrate-carbohydrate interactions. (PubMed, Eur J Med Chem) - "When evaluated as potential antidotes for heparin and fondaparinux-mediated blood coagulation, the highly guanidine-substituted HP mimetics displayed sub-micromolar antagonist potency. NMR studies further confirmed the carbohydrate-carbohydrate interactions between fondaparinux and the HP mimetics, providing a mechanistic basis for the observed activity and introducing a new strategy to block HP-mediated biological functions."

Journal • Oncology

MERCURION-IPF: Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P3 | N=196 | Not yet recruiting | Sponsor: Argyrios Tzouvelekis

New P3 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

The Necessity to Provide an Informed Choice Regarding Venous Thromboembolism Prophylaxis: A Single-Centre Study Observing Clinician Adherence and Opinions on Venous Thromboembolism Prophylaxis. (PubMed, Cureus) - "These are often done via nonpharmacological methods, such as anti-embolic (TED™) stockings, or with pharmacological methods, such as low molecular weight heparin (LMWH), which consists of medications such as dalteparin...Fondaparinux sodium, a fully synthetic alternative, offers a non-animal-derived option, yet its use remains limited...This demonstrates a clear health inequality. Educational initiatives and institutional protocols are recommended to promote patient-centred care and ensure ethical prescribing consistent with individual values."

Journal • Cardiovascular • Venous Thromboembolism

When pregnancy, HIT, and stroke collide: Navigating complex thrombotic care in a community-based setting (ASH 2025) - "Case Presentation: A 30-year-old woman, gravida 1 para 0, with a history of unprovoked lower extremity deep vein thrombosis (DVT) on chronic rivaroxaban for secondary prophylaxis was transitioned to low-molecular-weight heparin (enoxaparin) upon confirmation of pregnancy at 7 weeks' gestation...Enoxaparin was discontinued, and argatroban was initiated post-EVT, later transitioning to subcutaneous danaparoid, and ultimately fondaparinux for the remainder of her pregnancy...Another important feature of this case is that it was successfully managed entirely within a regional community hospital system, allowing the patient to stay close to her family and access local rehabilitation services. This case report highlights the ability of community-based hospitals to provide high-acuity, patient-centered care through strong interdisciplinary collaboration."

Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Thrombocytopenia • Thrombosis